Tulare-Kings Chapter CAMLT

Annual Seminar Series

Saturday, February 29 and Sunday March 1st, 2020

Visalia Convention Center 303 E. Acequia, Visalia, CA

12 CE’s

Saturday 8:15—11:45 a.m.  3.0 CE hrs. Level: Intermediate

Katherine Whelchel, MT (ASCP) SH, Technical Sales Representative

Sponsor: Diagnostic Stago, Inc.

“Thrombosis: What’s The Risk? Will I be one of the unfortunate ones?”

Saturday 1:00—4:30 p.m.  3.0 CE hrs. Level: Intermediate

Monet N. Sayegh, M.D., Physician Consultant

Sponsor: Siemens

“High-Sensitivity Cardiac Troponin I Assay in the Management of Acute Coronary Syndrome” and “Clinical Utility of Prostate Specific Antigen Isoforms in Prostate Cancer Management”

Sunday 8:15—11:45 a.m.  3.0 CE hrs. Level: Basic/Intermediate

Thomas Bane, PhD, PPM, Associate Director, Medical & Scientific Affairs

Sponsor: Beckman-Coulter

“Drugs of Abuse”

“Evolving Use of Cardiac Troponins in the Emergency Department”

Sunday 1:00-4:30 p.m.  3.0 CE hrs. Level: Basic/Intermediate

Moe R. Abouzari, DPM, MBA, Medical Science Liaison

Sponsor: ThermoFisher Scientific

David S. Hewitt, M.D. Kaweah Delta Laboratory Medical Director, Visalia, CA

“Procalcitonin: A Tool to Assist in Antibiotic Stewardship and Sepsis.” with Case Studies

Tulare-Kings Registration Form

Name: _______________________________________________ Address: ____________________________________________

City: ___________ State: _____ Zip Code: _______ Phone: _______________ Email: ________________________

CAMLT member? Yes   No   Senior? Yes (deduct $2.50 per 3 CE’s) No   License #:________________

Circle Workshop Choices: Sat AM: Thrombosis   Sat PM: Troponin/PSA

Sun AM: Drugs of Abuse/Cardiac Troponins   Sun PM: Procalcitonin

FEE

<table>
<thead>
<tr>
<th></th>
<th>0.5 day</th>
<th>1 day</th>
<th>1.5 day</th>
<th>2 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$35.00</td>
<td>$60.00</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Non Member</td>
<td>$45.00</td>
<td>$80.00</td>
<td>$110.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Student</td>
<td>$ 5.00</td>
<td>$10.00</td>
<td>$ 15.00</td>
<td>$ 20.00</td>
</tr>
</tbody>
</table>

FEE ENCLOSED: __________ DATE: _________ I would like confirmation by EMAIL TEXT MAIL Deadline Thursday, Feb 27th. If you register late, let me know you are attending via phone or email and you can pay at the door (cash or check only). Make check payable to: Tulare-Kings CAMLT and mail c/o 2845 S. Conyer St. Visalia, CA 93277.
Saturday, February 29, 2020  AM session

Course Title: “Thrombosis: What’s the Risk? Will I be one of the unfortunate ones?”

Course Outline: Acquired and inherited thrombotic risk is multifaceted. Patient thrombotic risk depends on many independent but also inter-dependent factors. Our session will explore both genetic and external risk factors, what testing should be done, if any, and how the hemostasis laboratory is part of the diagnostic team.

Objectives:
1. List genetic factors potentially involved in thrombosis, including Protein C, Protein S, Antithrombin and Factor V Leiden.
2. Discuss Lupus Anticoagulants and their role in Thrombosis.
3. Describe situational risk in thrombosis, such as malignancies, air travel and high-risk surgeries.
4. Evaluate approaches to thrombosis testing: whom and what do we test?
5. Summarize thrombosis risk in case studies and how it relates to the diagnostic team.

Saturday, February 29, 2020  PM session

Course Title: “High-Sensitivity Cardiac Troponin I Assay in the Management of Acute Coronary Syndrome” and “Clinical Utility of Prostate Specific Antigen Isoforms in Prostate Cancer Management.”

Course Outline 1: Acute Coronary Syndrome (ACS) is characterized by an imbalance between myocardial oxygen supply and demand. The most common cause is the reduced myocardial perfusion that results from Coronary Artery narrowing caused by a non-occlusive thrombus that has developed on a disrupted atherosclerotic plaque. Non-ST segment elevation myocardial infarction (NSTEMI) and unstable angina (UA) are considered closely related conditions: pathogenesis and clinical manifestations are similar but differing severity. The difference primarily in whether the ischemia is severe enough to cause sufficient damage to release detectable quantities of a marker of myocardial injury (Troponin). In this session, we will discuss highly sensitive troponin (hscTn) testing in the management of patients who present with symptoms consistent with acute coronary syndrome in the ED.

Objectives:
1. Describe the pathology involved in hscTn release.
2. Understand how hscTn is used to diagnose an AMI in a NSTEMI patient using the most recent guidelines.
3. Understand the relevance of hscTn elevations in disease states unrelated to coronary atherosclerosis.

Course Outline 2: “Clinical Utility of Prostate Specific Antigen Isoforms in Prostate Cancer Management.”

Biomarkers play a useful role in the diagnosis and treatment of cancer. The use of PSA, along with a digital rectal exam, can detect prostate cancer as much as 5-10 years earlier than a digital rectal exam alone. However, the current PSA test is limited in both sensitivity and specificity, resulting in both missed cancers and unnecessary biopsies. This seminar discussed the current utility of PSA testing, along with newer methods to improve specificity and sensitivity, including ratio testing with free to total PSA, and direct detection of the complexed PSA isoform.

Objectives:
1. Describe the role that PSA plays in the diagnosis and monitoring of prostate cancer.
2. Understand the value that ratios and isoforms can play in improving PSA testing.
3. List some of the advantages that complexed PSA adds to Total PSA performance.

Sunday, March 1, 2020 AM session

Course Title: “Evolving Use of Cardiac Troponin in the Emergency Department.”

Course Outline: The diagnosis of a myocardial infarction is a complex medical decision requiring the cooperative collaboration and timely flow of accurate procedures and information between several key hospital personnel from nurses and phlebotomists to the laboratorian and back to the medical specialists in order to ensure optimal patient outcomes.

Objectives:
1. Discuss key analytical and clinical terminology.
2. Relate to the challenges facing the ER in the rapid evaluation of potential Acute Myocardial Infarction.
3. Synthesize the recent research updates and trends surrounding the use of cardiac troponins.
4. Discuss the concepts behind measuring troponins deltas and establishing early rule-in/rule-out protocols using serial troponin measurements and describe the basic laboratory and clinical benefits of high sensitivity troponin.
Course Title 2: “Drugs of Abuse.”

Course Outline: A drug of abuse (DOA) is any drug, chemical or plant product, misused for recreational purposes. These include the expected, opioids and pain medication as well as the unexpected OTC medication and steroids. At the crossroads of drug abuse is the ever changing landscape of available drugs, detection and the law. Adapting your lab to the needs of the local population and legal requirements will be based upon the who, what and how of your labs specific capabilities. In this session, we will discuss the basics of matching assay design, capabilities, needs, local laws and case studies from workplace to Olympic testing.

Objectives:
1. Describe the basics of DOA screen design.
2. Discern potential sources of interference.
3. Correlate the needs of the hospital population with local law and lab-specific capabilities.

Sunday, March 1, 2020 PM session

Course Title: “Procalcitonin, A Tool to Assist in Antibiotic Stewardship and Sepsis.”

Course Outline: Describe the pathophysiology and kinetics of Procalcitonin (PCT) utilization and compare its value to other commonly used biomarkers, and finally review actual patient cases demonstrating PCT functionally in assessing patient health. This program is designed for basic to intermediate audiences.

Objectives: By completion of this program the participant should be able:
1. Describe the pathophysiology of PCT and describe its clinical utilization with the inpatient care arena.
2. Formulate the relevance of values associated with PCT serial measurement and apply these values toward antibiotic stewardship.
3. Discuss the value of PCT testing within the hospital setting and plan to discuss protocol development with other relevant departments.

Tulare Kings CAMLT c/o
2845 South Conyer Street
Visalia, CA 93277

TO:

12 CEU’s
Feb 29th and March 1st, 2020
Sponsored by: Beckman-Coulter, Siemens, Stago, ThermoScientific Inc.